3 weeks ago
JM Financial Sees 25-35% Upside in Three Buy Stocks
A company called JM Financial studies businesses to help people decide where to put their money, and it says three companies look like smart buys.
These are called 'Buy' recommendations, which means the experts think buying their shares could be a good idea.
The first is Ventive Hospitality, a hotel company that had a weak recent quarter because costs were high in the Maldives.
Even so, the company plans to double its hotel portfolio over the next five years.
The second is Neuland Laboratories, which makes ingredients for medicines and is growing very fast.
It is about to open a new factory that makes special medicine ingredients called peptides.
The third is Metropolis Healthcare, which runs labs that do medical tests, and it expects to grow by doing more tests and working more efficiently.
JM Financial thinks these companies' earnings could grow a lot over the next few years.
But buying stocks is always risky, so people should think carefully and talk to a trusted financial advisor first.
JM Financial retained 'Buy' ratings on Ventive Hospitality, Neuland Laboratories and Metropolis Healthcare, seeing 25% to 35% upside potential.
Ventive Hospitality got a 12-month target price of Rs 840 (about 35% upside) despite a soft June quarter driven by higher Maldives operating costs.
Neuland Laboratories received a target price of Rs 25,819 (about 29% upside), with its first commercial-scale peptide manufacturing facility on track for commissioning next month.
Metropolis Healthcare received a target price of Rs 734 (about 25% upside), guided by 14-15% near-term growth driven by 9-10% volume expansion.
JM Financial projects FY26-FY29 revenue CAGRs of about 12% for Ventive, 21% for Neuland and 16% for Metropolis Healthcare.
- Who
- JM Financial brokerage and the three companies it rates as 'Buy': Ventive Hospitality, Neuland Laboratories and Metropolis Healthcare.
- What
- JM Financial retained 'Buy' ratings on three stocks across hospitality, pharmaceuticals and diagnostics, with 25% to 35% upside potential.
- Where
- India-focused companies, with Ventive Hospitality also operating a business in the Maldives.
- When
- The latest JM Financial report was released after the companies' June quarter results, with Neuland's peptide facility commissioning expected next month.
- Why
- The brokerage sees growth from Ventive's portfolio expansion, Neuland's peptide opportunity and strong growth, and Metropolis's volume growth and margin improvements.
Key facts
- Brokerage
- JM Financial
- Rating
- Buy (retained) on all three stocks
- Upside potential
- 25% to 35% from current levels
- Ventive Hospitality target price
- Rs 840 (about 35% upside)
- Neuland Laboratories target price
- Rs 25,819 (about 29% upside)
- Metropolis Healthcare target price
- Rs 734 (about 25% upside)
- Key catalyst
- Neuland's commercial-scale peptide facility commissioning next month
- Ventive growth plan
- Double portfolio over the next five years
Quotes
JM Financial analyst
Analyst from JM Financial
“With crude prices having normalised, we do not view this quarter’s cost overshoot as structural.”
financialexpress.com
“Management remains confident of 20%+ YoY growth for FY27 and FY28.”
financialexpress.com







